Comparative safety of topical calcipotriol (0.005%) versus topical corticosteroid (betamethasone 0.1%) in plaque type psoriasis
Keywords:
Safety, calcipotriol, corticosteroid (betamethasone), plaque type psoriasisAbstract
Objective To compare the safety of topical calcipotriol (0.005%) and topical corticosteroid (betamethasone 0.1%) in the treatment of plaque type psoriasis. Patients and methods A clinical trial was carried out from January 2012 to August 2012 and patients of plaque type psoriasis attending outpatient department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Dhaka were the study population. Patients were divided into two groups, group A (n=15) was treated with topical calcipotriol (0.005%) ointment and group B (n=15) with topical corticosteroid (betamethasone 0.1%) ointment for 8 weeks. Results Adverse effects were found in 11 (73.3%) respondents in group A and 10 (66.7%) in group B. Among the adverse effects, desquamation, dry skin, irritation, itching, burning sensation, telangiectasia were commonly found. Conclusion The safety level of topical calcipotriol (0.005%) is almost same as that of betamethasone in the treatment of plaque type psoriasis.ÂReferences
Neimann AL, Porter SB, Elfand JM. The epidemiology of psoriasis. Expert Rev Dermatol. 2006;1:63-75.
Fenton C, Plosker G. Calcipotriol/Betamethasone dipropionate: A review. Am J Clin Dermatol. 2004;5:463-78.
Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther. 2000;25:2-10.
Douglas WS, Poulin Y, Decroix J. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:31-5.
Gelfand JM, Weinstein R, Porter SB. Prevalence and treatment of psoriasis in the United Kingdom. Arch Dermatol. 2005;141:1537-41.
Charakida A, Dadzie O, Teixeira F. Calcipotriol/Betamethasone dipropionate for the treatment of psoriasis. Expert Opin Pharmacother. 2006;7:597-606.
Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2006;20:39-44.
Langely RG, Krueger GG, Griffiths, CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum. 2005;64:18-23
Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol. 1999;26:723-33.
Guenther L, Cambazard F, Van de Kerkhof PCM. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147:316-23.
Kaufmann R, Bibby AJ, Bissonnette R. A new calcipotriol/betamethasone dipropionate formulation is an effective once daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389-93.
Kragballe K, Gjertsen B, de Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337:193-6.
Guenther LC. Calcipotriol/Betamethasone dipropionate: Daivobet/Dovobet. Therapy. 2005;2:343-48.
Cassano N, Miracapillo A, Coviello C et al. Treatment of psoriasis vulgaris with the two-compound product Calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig. 2006;26:227-33.
Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64:65-8.
Molin L. Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology. 1999;198:375-81.
Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol. 1992;26:736-43.
Kragballe K, Austad A. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product in the treatment of psoriasis. Br J Dermatol. 2006;6:1155-60.
Dahri GM,. Samdani AJ, Qazi N, Laghari MJ et al. To compare the role of calcipotriol alone versus combination with betamethasone in mild to moderate psoriasis. Sindh Univ Res J. 2010;42:69-72.
Johann EG and James TE. Psoriasis. In: Wolff K, Goldsmith SA, Katz SI et al., editors. Fitzpatrick’s Dermatology in General Medicine. 7th edn. San Fransisco, USA; McGraw-Hill; 2008. P.169-93.
